Manchester-based medical diagnostics company Premaitha Health has signed an exclusive Russia distribution agreement for its flagship IONA test – the CE marked non-invasive prenatal screening test.
The deal has been struck with GeNext LLC, a company dedicated to providing high quality molecular diagnostic products and will open up a key new market for Premaitha.
“We are delighted to have signed this agreement with GeNext to provide the IONA test in Russia,” said Premaitha chief executive Dr Stephen Little. This is a new territory for Premaitha and it enables us to establish a local laboratory offering routine non-invasive prenatal screening. With the signing of this latest agreement, Premaitha is demonstrating its ability to develop a network of partners servicing many countries across the globe.”
GeNext chief executive Vitali Proutski said: “This is an extremely important alliance for GeNext, as there is compelling clinical evidence to support the benefits of NIPT, and we believe Premaitha’s IONA system is the market leading product. We have built up significant expertise in the distribution of molecular diagnostics and the inclusion of the IONA® test within our portfolio will significantly enhance our offering.”
The deal follows other major breakthroughs for the IONA test, including deals to offer the service in Eastern Europe and India and the recommendation by the UK’s National Screening Committee that the test should be routinely offered to the NHS.
See the article in full at BusinessDesk.com